Product | Indication | Dosage form | Strength |
---|---|---|---|
Fingolimod | Multiple sclerosis | Capsules | 0.5 mg |
Fluconazol | Antifungal | Hard capsules | 50, 100, 150 and 200 mg |
Fluconazol | Antifungal | Powder for oral suspension | 200 mg/5ml |
Flupentixol decanoate | Schizophrenia | Injection | 10mg/ 0,5 ml; 20mg/ ml; 40mg/ ml; 200mg / 10 ml |
Imidapril * | Hypertension | Tablets | 5, 10 and 20 mg |
Ketorolac | Analgesic | Film-coated tablets | 10 mg |
Lacosamide | Epilepsy | Oral solution | 10 mg/ml syrup |
Levetiracetam | Epilepsy | Film-coated tablets | 250, 500, 750 and 1000 mg |
Levetiracetam | Epilepsy | Granules for oral solution | 250, 500, 750, 1000 and 1500 mg |
Levetiracetam | Epilepsy | Oral solution | 100 mg/ml |
Levodopa/benserazide | Parkinson | Tablets | 50 mg + 12.5mg 100 mg + 25 mg 200 mg + 50 mg |
Levomepromazine | Psychosis | Oral solution | 40 mg/ml |
Levomepromazine | Psychosis | Solution for injection | 25 mg/ml |
Levomethadone ** | Opioids substitution | Oral solution | 5mg/ ml (bottle 500ml and 1000ml) |
Levomethadone ** | Severe pain | Oral drops, solution | 5mg/ ml (bottle 20ml) |
Lisinopril | Hypertension | Tablets | 5 and 20 mg |
Lisinopril + HCTZ | Hypertension | Tablets | 20/12.5 mg |
Loratadine | Allergy | Film-coated tablets | 10 mg |
Melperone | Psychomotor agitation and sleep | Film-coated tablets | 10 mg, 25 mg, 50mg and 100 mg |
Melperone Forte | Psychomotor agitation and sleep | Oral solution | 25mg/ 5 ml |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.